K

Kolon Life Science Inc
KOSDAQ:102940

Watchlist Manager
Kolon Life Science Inc
KOSDAQ:102940
Watchlist
Price: 61 400 KRW 3.02% Market Closed
Market Cap: ₩762.6B

Net Margin

8.4%
Current
Improving
by 32.9%
vs 3-y average of -24.5%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
8.4%
=
Net Income
₩17.8B
/
Revenue
₩211.1B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
8.4%
=
Net Income
₩17.8B
/
Revenue
₩211.1B

Peer Comparison

Country Company Market Cap Net
Margin
KR
Kolon Life Science Inc
KOSDAQ:102940
762.8B KRW
Loading...
US
Eli Lilly and Co
NYSE:LLY
964.8B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.9B USD
Loading...
CH
Roche Holding AG
SIX:ROG
268.4B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
267.4B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
149.5B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.6B EUR
Loading...

Market Distribution

Higher than 78% of companies in Korea
Percentile
78th
Based on 2 632 companies
78th percentile
8.4%
Low
-168 471.3% — -2.9%
Typical Range
-2.9% — 5.8%
High
5.8% — 21 012.5%
Distribution Statistics
Korea
Min -168 471.3%
30th Percentile -2.9%
Median 1.9%
70th Percentile 5.8%
Max 21 012.5%

Kolon Life Science Inc
Glance View

Market Cap
762.6B KRW
Industry
Pharmaceuticals

KOLON Life Science, Inc. engages in the manufacture and sale of pharmaceuticals and environment materials. The company is headquartered in Seoul, Seoul and currently employs 451 full-time employees. The company went IPO on 2009-04-07. The firm operates its business under two segments. The Chemical Business segment produces and sells raw drug products, which are the raw materials of new drugs and generic drugs, antibacterial agents that suppress bacterial growth, water treatment agents for environmental purification, and functional material products for cosmetics. The Bio Business segment manufactures and sells bio new medicines based on cell gene therapy products.

Intrinsic Value
26 339.78 KRW
Overvaluation 57%
Intrinsic Value
Price
K
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
8.4%
=
Net Income
₩17.8B
/
Revenue
₩211.1B
What is Kolon Life Science Inc's current Net Margin?

The current Net Margin for Kolon Life Science Inc is 8.4%, which is above its 3-year median of -24.5%.

How has Net Margin changed over time?

Over the last 3 years, Kolon Life Science Inc’s Net Margin has increased from -3% to 8.4%. During this period, it reached a low of -60.7% on Sep 30, 2024 and a high of 8.4% on Oct 30, 2025.

Back to Top